William Barchuk

1.2k total citations
22 papers, 677 citations indexed

About

William Barchuk is a scholar working on Rheumatology, Immunology and Epidemiology. According to data from OpenAlex, William Barchuk has authored 22 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 7 papers in Immunology and 6 papers in Epidemiology. Recurrent topics in William Barchuk's work include Rheumatoid Arthritis Research and Therapies (6 papers), Spondyloarthritis Studies and Treatments (5 papers) and Liver Diseases and Immunity (4 papers). William Barchuk is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Spondyloarthritis Studies and Treatments (5 papers) and Liver Diseases and Immunity (4 papers). William Barchuk collaborates with scholars based in United States, Canada and Belgium. William Barchuk's co-authors include Leah Teoh, Edward A. Panacek, Rodger D. MacArthur, Mark Miller, Timothy Albertson, David H. Johnson, Steven Fischkoff, Steven B. Johnson, David H. Johnson and Christopher J. Doig and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Allergy and Clinical Immunology and Critical Care Medicine.

In The Last Decade

William Barchuk

21 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Barchuk United States 10 348 220 112 85 79 22 677
Luis M. Beltrán Spain 16 254 0.7× 54 0.2× 89 0.8× 135 1.6× 61 0.8× 50 1.1k
Jérémie Lemarie France 15 129 0.4× 254 1.2× 67 0.6× 46 0.5× 15 0.2× 39 616
Gerry S. San Pedro United States 4 497 1.4× 346 1.6× 172 1.5× 39 0.5× 18 0.2× 8 936
Georgina Peñarroja Spain 10 360 1.0× 44 0.2× 33 0.3× 41 0.5× 73 0.9× 12 774
Florent Artru France 15 570 1.6× 48 0.2× 65 0.6× 51 0.6× 24 0.3× 57 934
Maria Jimenez Canada 6 332 1.0× 327 1.5× 164 1.5× 40 0.5× 8 0.1× 6 831
Aurélie Gouél‐Cheron France 12 120 0.3× 120 0.5× 50 0.4× 41 0.5× 14 0.2× 28 391
Zahid A. Saeed United States 14 473 1.4× 123 0.6× 25 0.2× 104 1.2× 15 0.2× 31 2.1k
Erzhen Chen China 14 174 0.5× 189 0.9× 41 0.4× 52 0.6× 9 0.1× 52 771
Dragan Djordjević Serbia 12 256 0.7× 83 0.4× 47 0.4× 19 0.2× 25 0.3× 73 698

Countries citing papers authored by William Barchuk

Since Specialization
Citations

This map shows the geographic impact of William Barchuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Barchuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Barchuk more than expected).

Fields of papers citing papers by William Barchuk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Barchuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Barchuk. The network helps show where William Barchuk may publish in the future.

Co-authorship network of co-authors of William Barchuk

This figure shows the co-authorship network connecting the top 25 collaborators of William Barchuk. A scholar is included among the top collaborators of William Barchuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Barchuk. William Barchuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Watkins, Timothy R., Quan Dong Nguyen, David K. Scales, et al.. (2024). Filgotinib in Active Noninfectious Uveitis. JAMA Ophthalmology. 142(9). 789–789. 7 indexed citations
2.
Levy, Cynthia, Stephen H. Caldwell, Parvez Mantry, et al.. (2024). Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study. Clinical and Translational Gastroenterology. 15(8). e00744–e00744. 1 indexed citations
3.
Thorburn, Douglas, Diana Julie Leeming, William Barchuk, et al.. (2024). Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis. Hepatology Communications. 8(7). 5 indexed citations
4.
Trauner, Michael, Cynthia Levy, Atsushi Tanaka, et al.. (2023). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS). Journal of Hepatology. 78. S12–S13. 8 indexed citations
5.
Maksymowych, Walter P., Mikkel Østergaard, Robert Landewé, et al.. (2021). Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Lara D. Veeken. 61(6). 2388–2397. 16 indexed citations
6.
Baraliakos, Xenofon, Mikkel Østergaard, R. B. M. Landewé, et al.. (2021). OP0141 EFFECTS OF FILGOTINIB ON SPINAL LESIONS IN ANKYLOSING SPONDYLITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE TORTUGA TRIAL. Annals of the Rheumatic Diseases. 80. 83–84. 1 indexed citations
7.
Maksymowych, Walter P., Mikkel Østergaard, Robert Landewé, et al.. (2021). Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). Lara D. Veeken. 61(5). 2063–2071. 19 indexed citations
8.
Genovese, Mark C., Alberto Spindler, Akira Sagawa, et al.. (2020). Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. The Journal of Rheumatology. 48(7). 969–976. 15 indexed citations
9.
Maksymowych, Walter P., Mikkel Østergaard, R. B. M. Landewé, et al.. (2020). THU0377 IMPACT OF FILGOTINIB ON STRUCTURAL LESIONS IN THE SACROILIAC JOINTS AT 12 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE DOUBLE-BLIND, RANDOMIZED TORTUGA TRIAL. Annals of the Rheumatic Diseases. 79. 421–422. 4 indexed citations
10.
Maksymowych, Walter P., Yuan Tian, William Barchuk, et al.. (2020). FRI0285 FILGOTINIB TREATMENT RESULTS IN REDUCTION OF BIOMARKERS ASSOCIATED WITH DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS. Annals of the Rheumatic Diseases. 79. 730–731. 1 indexed citations
11.
12.
Genovese, Mark C., Alberto Spindler, Akira Sagawa, et al.. (2019). SAT0089 SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY. Annals of the Rheumatic Diseases. 78. 1109–1110. 2 indexed citations
13.
Deodhar, Atul, Alice B. Gottlieb, Wolf‐­Henning Boehncke, et al.. (2018). OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 77. 201–201. 9 indexed citations
14.
15.
Barchuk, William, John M. Lambert, Rainard Fuhr, et al.. (2014). Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma. Pulmonary Pharmacology & Therapeutics. 29(1). 15–23. 18 indexed citations
16.
Barchuk, William, et al.. (2013). A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. Journal of Allergy and Clinical Immunology. 132(4). 838–846.e6. 24 indexed citations
17.
Panacek, Edward A., John C. Marshall, Timothy E. Albertson, et al.. (2004). Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*. Critical Care Medicine. 32(11). 2173–2182. 267 indexed citations
18.
MacArthur, Rodger D., Mark Miller, Timothy Albertson, et al.. (2004). Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial. Clinical Infectious Diseases. 38(2). 284–288. 196 indexed citations
19.
Gallagher, James J., Charles J. Fisher, Bruce W. Sherman, et al.. (2001). A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome. Intensive Care Medicine. 27(7). 1169–1178. 35 indexed citations
20.
Fernandes, Helen, et al.. (1995). REGULATION OF CLL BY INTERLEUKIN-10 - ROLE OF ANTISENSE IL-10. Oncology Reports. 2(6). 985–9. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luis M. Beltrán Breakdown of academic impact, for papers by Jérémie Lemarie Breakdown of academic impact, for papers by Gerry S. San Pedro Breakdown of academic impact, for papers by Georgina Peñarroja Breakdown of academic impact, for papers by Florent Artru Breakdown of academic impact, for papers by Maria Jimenez Breakdown of academic impact, for papers by Aurélie Gouél‐Cheron Breakdown of academic impact, for papers by Zahid A. Saeed Breakdown of academic impact, for papers by Erzhen Chen Breakdown of academic impact, for papers by Dragan Djordjević
Rankless by CCL
2026